Hormonal
Olanzapine, but not aripiprazole, causes significant postprandial hyperinsulinemia and elevations in GLP-1 and glucagon, coincident with insulin resistance.
Olanzapine uniquely disrupts your gut-hormone signaling (GLP-1 and glucagon) after eating, leading to high insulin spikes. This is different from other antipsychotics like aripiprazole, which cause insulin resistance without these specific hormonal spikes. This suggests olanzapine has a more complex impact on digestion and metabolism.
We found that olanzapine... causes significant elevations in postprandial insulin, glucagon-like peptide 1 (GLP-1), and glucagon coincident with insulin resistance compared with placebo. Aripiprazole... induces insulin resistance but has no effect on postprandial hormones.
Why this rating
Controlled meal challenge with detailed hormonal sampling; small sample size limits generalizability of the specific hormonal magnitude.
Source
Antipsychotic-Induced Insulin Resistance and Postprandial Hormonal Dysregulation Independent of Weight Gain or Psychiatric Disease
Karen L. Teff et al. · Diabetes · 2013
DOI 10.2337/db13-0430
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →